Chuck Bramlage has been appointed President and Chief Executive Officer of Pearl Therapeutics, replacing interim President and CEO Howard Rosen. Pearl, a California pharmaceutical company developing inhaled treatments for COPD and asthma, was founded in 2006. Its lead product, PT 003, a LAMA/LABA combination MDI, is moving into Phase 2b trials.
Bramlage was most recently President of Pharmaceutical Products at Covidien and was previously Vice President of Respiratory Global Commercial Development and Vice President of US Respiratory and Cardiovascular Marketing at GlaxoSmithKline during launches of Advair and Flovent. He has also held positions at Valeant and at BattellePharma.
Read the company’s press release.
